Vikram Karnani joined Collegium Pharmaceutical in November 2024 as President and Chief Executive Officer. Prior to joining Collegium, Mr. Karnani served as Executive Vice President and President, Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, where he was responsible for driving the global commercial strategy for Amgen’s portfolio of rare disease medicines. Prior to joining Amgen through its 2023 acquisition of Horizon, Mr. Karnani held numerous roles of increasing responsibility at Horizon that culminated in his position as Executive Vice President and President of Global Commercial and Medical Affairs, responsible for Horizon’s portfolio of rare disease medicines. Before joining Horizon in 2014, Mr. Karnani served as Vice President of the Therapeutics and Cell Therapy business and held leadership roles in strategy and business development at Fresenius Kabi. Mr. Karnani received a B.S.E.E. in Electrical Engineering from the University of Mumbai, India; an M.S.E.E. in Electrical Engineering from Case Western Reserve University; and an M.B.A. from the Kellogg School of Management at Northwestern University.